Who
Francisco D. Salva
President and CEO
Company insider
Files Form 4 as: President and CEO, Azitra; Director, Vincerx Pharma.
In numbers
- Trades disclosed
- 20
- Buys
- 1
- Sells
- 0
- Bought
- $100K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 Dec 2020
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | AZTR AzitraBiotechnology | SEC FORM 4 Code C | —4,064,050 | filing |
| 16 Jun 2026filed 18 Jun 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code C | —500 | filing |
| 16 Jun 2026filed 18 Jun 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code C | —500 | filing |
| 16 Jun 2026filed 18 Jun 2026 | AZTR AzitraBiotechnology | SEC FORM 4 Code C | —4,064,050 | filing |
| 20 Apr 2026filed 22 Apr 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,879 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,879 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —500 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,064,050 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,064,050 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —500 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,064,050 | filing |
| 18 Mar 2026filed 20 Mar 2026 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code P | —4,064,050 | filing |
| 19 Dec 2025filed 22 Dec 2025 | AZTR Azitraoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,309 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | AZTR AzitraBiotechnology | SEC FORM 4 Bought | $100K333,300 at $0.30 | filing |
| 21 Jun 2023filed 23 Jun 2023 | AZTR AzitraBiotechnology | SEC FORM 4 Code A | $25K5,000 at $5.00 | filing |
| 25 May 2023filed 30 May 2023 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 May 2022filed 31 May 2022 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 13 May 2021filed 14 May 2021 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Dec 2020filed 28 Dec 2020 | Vincera Pharmaoption or derivative | SEC FORM 4 Code A | —6,667 at $0.00 | filing |
News
Azitra (NYSEAMERICAN:AZTR) Shares to Reverse Split on Monday, October 26thAZTR · tickerreport.com · 18 Oct 2026Azitra, Inc. (NYSEAMERICAN:AZTR) Stock Short Interest Declines 65.7%AZTR · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Francisco D. Salva; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.